UniProtKB/Swiss-Prot P67775 : Variant p.Tyr127Cys
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform
Gene: PPP2CA
Feedback ?
Variant information
Variant position:
127
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Tyrosine (Y) to Cysteine (C) at position 127 (Y127C, p.Tyr127Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from large size and aromatic (Y) to medium size and polar (C)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In HJS3; almost complete loss of phosphatase activity in an in vitro assay; strong decrease in C-terminal methylation; no effect on the interaction with PP2A subunit A PPP2R1A/PPP2R1B; decreased interaction with PP2A subunit B components PPP2R5A, PPP2R5B, PPP2R5C, PPP2R5D, PPP2R5E and PPP2R3A; no effect on interaction with PP2A subunit B component PPP2R2A.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
127
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
309
The length of the canonical sequence.
Location on the sequence:
YRERITILRGNHESRQITQV
Y GFYDECLRKYGNANVWKYFT
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human YRERITILRGNHESRQITQVY GFYDECLRKYGNANVWKYFT
Mouse YRERITILRGNHESRQITQVY GFYDECLRKYGNANVWKYFT
Rat YRERITILRGNHESRQITQVY GFYDECLRKYGNANVWKYFT
Pig YRERITILRGNHESRQITQVY GFYDECLRKYGNANVWKYFT
Bovine YRERITILRGNHESRQITQVY GFYDECLRKYGNANVWKYFT
Rabbit YRERITILRGNHESRQITQVY GFYDECLRKYGNANVWKYFT
Chicken YPERITILRGNHESRQITQVY GFYDECLRKYGNANVWKYFT
Slime mold YKDRVTILRGNHESRQITQVY GFYDECLRKYGNPNVWKLFT
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 309
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform
Active site
118 – 118
Proton donor
Binding site
117 – 117
Helix
121 – 127
Literature citations
De novo mutations affecting the catalytic C alpha subunit of PP2A, PPP2CA, cause syndromic intellectual disability resembling other PP2A-related neurodevelopmental disorders.
Reynhout S.; Jansen S.; Haesen D.; van Belle S.; de Munnik S.A.; Bongers E.M.H.F.; Schieving J.H.; Marcelis C.; Amiel J.; Rio M.; Mclaughlin H.; Ladda R.; Sell S.; Kriek M.; Peeters-Scholte C.M.P.C.D.; Terhal P.A.; van Gassen K.L.; Verbeek N.; Henry S.; Scott Schwoerer J.; Malik S.; Revencu N.; Ferreira C.R.; Macnamara E.; Braakman H.M.H.; Brimble E.; Ruzhnikov M.R.Z.; Wagner M.; Harrer P.; Wieczorek D.; Kuechler A.; Tziperman B.; Barel O.; de Vries B.B.A.; Gordon C.T.; Janssens V.; Vissers L.E.L.M.;
Am. J. Hum. Genet. 104:139-156(2019)
Cited for: INVOLVEMENT IN HJS3; VARIANTS HJS3 VAL-60; GLY-88; HIS-122; 125-GLN--LEU-309 DEL; CYS-127; HIS-131; ARG-191; 214-ARG--LEU-309 DEL; HIS-223; VAL-223; CYS-265; 295-ARG--LEU-309 DEL AND PHE-308 INS; CHARACTERIZATION OF VARIANTS HJS3 GLY-88; HIS-122; 125-GLN--LEU-309 DEL; CYS-127; HIS-131; ARG-191; 214-ARG--LEU-309 DEL; HIS-223; VAL-223; CYS-265; 295-ARG--LEU-309 DEL AND PHE-308 INS; CATALYTIC ACTIVITY; MUTAGENESIS OF ASP-85; CARBOXYMETHYLATION; INTERACTION WITH PP2A SUBUNIT A AND PP2A SUBUNITS B;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.